The HUMIRA® biosimilars market is projected to witness considerable growth over the coming years

Unlike other biosimilar markets, competition among follow-on products of HUMIRA® is very high and several eager companies are attempting to carve out a share of the multibillion-dollar opportunity associated with this blockbuster product

Roots Analysis has announced the addition of the “HUMIRA® (Adalimumab) Biosimilars – Pipeline Review and Partnerships” report to its list of offerings.

Detailed review of the adalimumab biosimilars pipeline and affiliated developer landscape, featuring a list of involved innovator companies and their respective therapy candidates. It includes insights based on the current status of biosimilar candidates, and important developer related details (including headquarters, and type of developer).

For additional details, please visit